Published in Trends Pharmacol Sci on December 01, 1992
SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev (1998) 4.19
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17
Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol (2010) 1.51
Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (1996) 1.11
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect (1994) 1.02
Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut (2002) 0.98
Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf (2012) 0.94
Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 0.93
Pharmacogene regulatory elements: from discovery to applications. Genome Med (2012) 0.91
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol (1994) 0.91
Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol (2008) 0.90
Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet (2014) 0.89
The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. Am J Obstet Gynecol (2012) 0.88
Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol (2012) 0.87
Sex differences in the inhibition of gamma-tocopherol metabolism by a single dose of dietary sesame oil in healthy subjects. Am J Clin Nutr (2008) 0.84
Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ Health Perspect (1997) 0.83
The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. Am J Obstet Gynecol (2013) 0.82
CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis. PLoS One (2013) 0.80
A case of Creutzfeldt-Jakob disease presenting with cortical deafness. J Neurol Neurosurg Psychiatry (1994) 0.80
Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr (2007) 0.77
Risk factors for drug-induced long-QT syndrome. Neth Heart J (2005) 0.77
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol (1999) 0.77
Familial Parkinson's disease and polymorphism at the CYP2D6 locus. J Neurol Neurosurg Psychiatry (1994) 0.76
Individual oral therapy with immediate release and effervescent formulations delivered by the solid dosage pen. J Pers Med (2012) 0.75
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. Clin Drug Investig (2017) 0.75
Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol (1995) 0.75
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet (1980) 5.68
Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J (1978) 3.90
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry (1997) 2.71
Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther (2011) 2.50
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
Susceptibility of pneumococci to nine antibiotics. Am J Med Sci (1965) 2.19
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (1984) 2.17
The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics (1992) 2.12
Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica (1979) 2.07
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology (1997) 1.94
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet (1983) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Poor metabolisers of debrisoquine reveal their true colours. Lancet (1989) 1.84
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev (1979) 1.71
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet (1999) 1.68
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut (2000) 1.68
Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci (1978) 1.55
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer (1996) 1.54
Candida at Boston City Hospital. Clinical and epidemiological characteristics and susceptibility to eight antimicrobial agents. Arch Intern Med (1970) 1.50
Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis (1997) 1.49
Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst (1992) 1.49
Isolation of Eikenella corrodens in a general hospital. Appl Microbiol (1973) 1.48
Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease. Mov Disord (2000) 1.48
Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res (1995) 1.46
CYP2D6 multiallelism. Methods Enzymol (1996) 1.45
The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol (1992) 1.44
A genetic polymorphism of the N-oxidation of trimethylamine in humans. Clin Pharmacol Ther (1987) 1.44
The metabolism of 14C-labelled trimethylamine and its N-oxide in man. Xenobiotica (1987) 1.44
CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst (1997) 1.43
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics (1995) 1.39
The long and the short of drug safety. Lancet (1993) 1.39
Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet (1993) 1.39
Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet (1992) 1.38
Microbiological investigation of Bartholin's gland abscesses and cysts. Am J Obstet Gynecol (1977) 1.35
A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet (1995) 1.33
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 1.31
The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol (2001) 1.30
Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man. Br J Clin Pharmacol (1984) 1.29
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics (1991) 1.27
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther (1981) 1.26
Molecular genotyping to predict debrisoquine hydroxylation phenotype. Lancet (1990) 1.25
Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet (1994) 1.23
Protecting poor metabolizers, a group at high risk of adverse drug reactions. Lancet (1983) 1.23
CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol (2000) 1.21
Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol (1999) 1.20
Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA (1988) 1.20
Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett (1996) 1.20
Amlodipine-induced gingival overgrowth. J Clin Periodontol (1994) 1.20
Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol (1983) 1.19
Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol (2000) 1.18
Trimethylaminuria ('fish-odour syndrome'): a study of an affected family. Clin Sci (Lond) (1988) 1.18
Trimethylaminuria: the detection of carriers using a trimethylamine load test. J Inherit Metab Dis (1989) 1.15
Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev (2001) 1.14
Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis (1997) 1.11
Toxicological implications of polymorphic drug metabolism. Ciba Found Symp (1980) 1.11
Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (1996) 1.11
CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics (1996) 1.11
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics (1996) 1.08
Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]. Br J Pharmacol (1979) 1.08
CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics (1998) 1.07
Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J (2003) 1.06
Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther (1979) 1.06
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res (1993) 1.06
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet (2000) 1.05
Interphase nuclear matrix and metaphase scaffolding structures. J Cell Sci Suppl (1984) 1.05
CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics (1997) 1.05
Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes Nutr (2007) 1.05
Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics (1996) 1.04
A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica (1980) 1.03
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther (1985) 1.03
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect (1994) 1.02
The relative importance of N-oxidation and N-demethylation in the metabolism of trimethylamine in man. Toxicology (1987) 1.02
Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer (2001) 1.02
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol (1995) 1.01
Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev (1999) 1.01
Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man. Biochem Pharmacol (1982) 1.00
Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol (1994) 1.00
Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther (1982) 1.00
Bacterial endocarditis due to an unusual species of encapsulated Neisseria. Neisseria mucosa endocarditis. Am J Dis Child (1971) 1.00
The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics (1998) 1.00
Metabolic polymorphisms. Pharmacol Ther (1993) 0.99